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Abstract
Using a laser-induced endothelial injury model, we examined thrombus formation in the microcirculation of wild-type and genetically altered mice by real-time in vivo microscopy to
analyze this complex physiologic process in a system that includes the vessel wall, the presence
of flowing blood, and the absence of anticoagulants. We observe P-selectin expression, tissue
factor accumulation, and fibrin generation after platelet localization in the developing thrombus in arterioles of wild-type mice. However, mice lacking P-selectin glycoprotein ligand 1
(PSGL-1) or P-selectin, or wild-type mice infused with blocking P-selectin antibodies, developed platelet thrombi containing minimal tissue factor and fibrin. To explore the delivery of
tissue factor into a developing thrombus, we identified monocyte-derived microparticles in human platelet–poor plasma that express tissue factor, PSGL-1, and CD14. Fluorescently labeled
mouse microparticles infused into a recipient mouse localized within the developing thrombus,
indicating that one pathway for the initiation of blood coagulation in vivo involves the accumulation of tissue factor– and PSGL-1–containing microparticles in the platelet thrombus expressing
P-selectin. These monocyte-derived microparticles bind to activated platelets in an interaction
mediated by platelet P-selectin and microparticle PSGL-1. We propose that PSGL-1 plays a
role in blood coagulation in addition to its known role in leukocyte trafficking.
Key words: blood coagulation • fibrin • thrombosis • endothelium • intravital microscopy

Introduction
P-selectin glycoprotein ligand 1 (PSGL-1)* and P-selectin
are vascular cell adhesion molecules that play a critical role
in leukocyte trafficking and lymphocyte migration (1–3).
P-selectin is expressed on activated platelets (4–7) and binds
to PSGL-1 on circulating leukocytes (8–10). Although the
contribution of these proteins to the inflammatory response
has been the subject of numerous studies, the role of these
proteins in hemostasis and thrombosis has not been eluciAddress correspondence to Bruce Furie, Center for Hemostasis and
Thrombosis Research, Research East 319, Beth Israel Deaconess Medical
Center, 330 Brookline Avenue, Boston, MA 02215. Phone: 617-6670620; Fax: 617-975-5505; E-mail: bfurie@caregroup.harvard.edu
Q. Liu’s present address is Department of Dermatology, Massachusetts
General Hospital, 55 Fruit St., Boston, MA 02114.
K. Croce’s present address is Department of Medicine, Brigham and
Women’s Hospital, 75 Francis St., Boston, MA 02115.
P. Gross’ present address is Department of Medicine, University of
Toronto, 30 Bond St., Toronto, Ontario M5B 1WB, Canada.
*Abbreviation used in this paper: PSGL-1, P-selectin glycoprotein ligand 1.
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dated. Using a shunt model in a baboon, we have previously demonstrated that infusion of blocking P-selectin antibodies decreases fibrin generation in the developing
experimental thrombus (11). This presented the first evidence
for a P-selectin–dependent pathway of blood coagulation. Although P-selectin up-regulates tissue factor expression in
monocytes (12), de novo synthesis of tissue factor is required and rapid fibrin generation could not be explained
by leukocyte incorporation into the developing thrombus.
A role for P-selectin or PSGL-1 has remained uncertain in
the mechanism of fibrin formation.
After vascular injury, extravasation of blood is minimized
by the rapid formation of intravascular thrombi composed
of platelets and fibrin (13). Tissue factor is the initial activator of the blood coagulation pathway that culminates in the
generation of a fibrin clot (14). An integral membrane protein, it is expressed on most nonvascular cells (15, 16). The
classical model has been that vascular injury leads to the ex-
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posure of flowing blood to extravascular cells expressing
tissue factor, with the concomitant rapid initiation of blood
coagulation. Low levels of tissue factor have been identified
circulating in normal plasma (17–19) and an in vitro
thrombosis model has been used to demonstrate tissue factor accumulation within the fibrin-dominated thrombus
upon perfusion of fresh human blood onto collagen-coated
slides or sections of pig arterial media (20). The transfer of
tissue factor particles from a monocyte-like cell line to the
platelet surface in vitro is dependent upon CD15 and tissue
factor (21), suggesting that blood-borne tissue factor accumulates in the thrombus in a mechanism that involves
CD15 and tissue factor on membranous particles bound to
P-selectin on platelets. Here, we test this hypothesis in in
vivo models that offer opportunities to analyze the initiation of thrombus formation in a complex physiologic system that includes the vessel wall, the presence of flowing
blood, and the absence of anticoagulants.
We have developed instrumentation for real-time imaging of multiple fluorescent components during thrombus
formation in the microcirculation of a living mouse using
intravital high speed microscopy (22). Using this system in
conjunction with a laser-induced endothelial injury model
(23), we demonstrate distribution of tissue factor throughout
the developing thrombus in vivo, although most tissue factor
is concentrated at the thrombus vessel wall interface (22).
In this study of in vivo thrombus formation in genetically
altered mice, we demonstrate P-selectin– and PSGL-1–dependent tissue factor accumulation and fibrin generation during arterial thrombus formation in vivo. Monocyte-derived
microparticles expressing tissue factor and PSGL-1 accumulate
on activated platelets expressing P-selectin, thus concentrating tissue factor to a level that triggers the initiation of
blood coagulation.

vein cannulus. Approximately 5 min later, an arteriole was identified and endothelial injury was induced using a pulsed nitrogen
dye laser applied through the microscope objective using the Micropoint laser system (Photonic Instruments). Multiple independent thrombi were generated, a new injury always upstream to
previous injuries, in different arterioles over the course of approximately 1 h.

Antibodies and Reagents
Mice were infused with 1.9 g/g mouse body weight of rat
anti–mouse P-selectin (BD Biosciences), 8 g/g body weight of
sheep anti–rabbit tissue factor (American Diagnostica, Inc.) or affinity-purified rabbit anti–mouse tissue factor (152–166) antibody, 2 g/g body weight of mouse anti–fibrin II  chain (Accurate Chemical), 0.1 g/g body weight of rat anti–mouse CD41
(BD Biosciences), 1 g/g body weight of chicken anti–rat IgG
(BD Biosciences), 4 g/g body weight of donkey anti–sheep IgG
(Molecular Probes), and 1 U/g body weight of hirudin (Calbiochem), where indicated. Alexa 350, Alexa 488, and Alexa 660
were conjugated to purified antibodies according to the Alexa
Fluor Protein Labeling Kit (Molecular Probes). The mouse anti–
fibrin II  chain–specific antibody binds to fibrin but does not
bind to fibrinogen (27).
Antibodies to mouse tissue factor were prepared by standard
methods (28) based upon a previous report (29). A synthetic peptide, mTF(152–166), representing residues 152–166 of mouse tissue factor with an additional NH2-terminal cysteine for purposes
of chemical linking, was synthesized. The sequence was verified
by automated Edman degradation and its molecular mass was
confirmed at 1,643.88 amu by mass spectroscopy. Rabbits were
immunized with 500 g of the peptide/KLH conjugate, and then
200 g of the peptide/KLH conjugate monthly. Anti-tissue factor peptide antibodies were purified by immunoaffinity chromatography using the synthetic peptide. Antiserum was applied to a
KLH-Sepharose column to remove anti-KLH antibodies. Antibodies that failed to bind were applied to a peptide-Sepharose
column, and bound antibody was eluted with 100 mM glycine,
pH 3.

Materials and Methods

Preparation of Microparticles

Intravital Microscopy

Isolation of Microparticles from Human Platelet-poor Plasma.
Venous blood was drawn from healthy volunteers into 4% sodium citrate or 50 mM EDTA (1:10 vol/vol) and a complete
EDTA-free protease inhibitor cocktail (Boehringer), and then
centrifuged at 25C at 2,500 g for 25 min. Platelet-poor plasma
was decanted. Flow cytometry demonstrated that 95% of all
particles were smaller than 1 m.
Mixed Leukocyte– and Platelet-derived Microparticles Generated from
Mouse Whole Blood. Blood was drawn from wild-type mice by
cardiac puncture and anticoagulated with sodium citrate as described above. For mouse preparations, 2% dextran in saline (molecular weight 160,000) was mixed (1:1 vol/vol) with the cell
suspension for 40 min at room temperature to sediment red cells.
Dextran-rich supernatant including leukocytes as well as residual
platelets were washed twice and resuspended in Hank’s buffer
containing 1 mM calcium chloride and the protease inhibitor
cocktail (Boehringer). 1.5 g/ml calcein AM was added to the
cells and microparticles were generated using 10 M A23187 for
20 min at room temperature. Cells were removed by centrifugation at 14,000 g in an Eppendorf microcentrifuge. Flow cytometry indicated that 98% of the particles present in the supernatant
were smaller than 1 m.

High speed intravital digital videomicroscopy was performed
as previously described (22).

Mice
PSGL-1 null mice, previously described (24, 25), backcrossed
five generations into a C57B6 background (N5), have been deposited at The Jackson Laboratory for distribution (B6.CgSelPltm1Fur). P-selectin/ (C57BL/6J-Selptm1Bay) and C57BL/6J
mice were obtained from The Jackson Laboratory. All procedures
were approved by the Animal Care and Use Committee of Beth
Israel Deaconess Medical Center.

Laser-induced Vessel Wall Injury
12–16-wk-old male mice were preanesthetized with ketamine,
xylazine, and atropine sulfate, and a trachea tube was inserted to
facilitate spontaneous respiration (22). Nembutal was administered through the jugular vein. The cremaster muscle, exteriorized in 4–7 min, was prepared for intravital microscopy (24, 26).
The microvasculature was visualized by transmission microscopy.
Antibodies in 200 l physiologic saline were infused via a jugular
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Microparticles Generated from Density Gradient–purified Human
Mononuclear Cells. Blood was obtained from human volunteers
into 4% sodium citrate (1:10 vol/vol) and an EDTA-free protease
inhibitor cocktail, and centrifuged at 200 g for 15 min. Blood was
layered on Ficoll-Paque and centrifuged at 400 g for 30 min at
4C. The interface cells were removed, washed with RPMI 1640
medium three times at 4C, and resuspended in RPMI 1640.
Platelet to mononuclear cell ratio, determined microscopically,
was typically 0.5:1. The cells were then incubated for 6 h with
100 ng/ml LPS (Escherichia coli serotype 055:B5; Sigma-Aldrich)
at 37C under 5% CO2, or 5.5 h with LPS followed by 20 min
with 10 M A23187 and a protease inhibitor cocktail. Cell suspensions were centrifuged for isolation of microparticles as described above.
Microparticles Generated from WEHI Cells. WEHI cells (American Type Culture Collection WEHI 274.1) were incubated for
40 min with calcein AM in Hank’s buffer and cultured in
DMEM. Microparticles were generated with the addition of 10
M A23187 for 20 min and a protease inhibitor cocktail. Cell
suspensions were centrifuged for isolation of microparticles as described above.

Mouse Microparticle Incorporation into Arterial Thrombi
Calcein-labeled microparticles were generated from density
gradient–purified mononuclear cells or from WEHI cells in cell
culture. Microparticles were isolated by ultracentrifugation at
150,000 g for 2 h at 10C. The pellet was resuspended in sterile
saline and evaluated for fluorescence intensity and size by flow
cytometry before infusion into an anesthetized mouse.

Purification and Analysis of Tissue Factor and
PSGL-1–bearing Microparticles
Tissue factor–bearing microparticles were isolated from human platelet-poor plasma or mononuclear cell supernatant using
polystyrene beads coated with anti-tissue factor antibodies. Polystyrene beads (4.5-m diameter; Polysciences) were washed
three times with PBS and incubated with polyclonal rabbit anti–
human tissue factor antibodies (American Diagnostics, Inc.) at
100 g/ml at 24C for 1 h. The beads were twice pelleted by
centrifugation and washed in PBS containing 1% BSA. To generate control beads, parallel preparations were performed with a
polystyrene bead coated with nonimmune IgG. Adsorption of
antibodies to beads was confirmed by flow cytometry. Mononuclear cell supernatant or platelet-poor plasma was mixed with
beads coated with anti-tissue factor antibodies or nonimmune
IgG for 18 h at 24C after preincubation of mononuclear cell supernatant or platelet-poor plasma with 8 g/ml human IgG or
rabbit IgG for 30 min to block Fc receptors. The beads were
centrifuged, washed twice with PBS/0.1% BSA, and resuspended
in the same buffer before evaluation by flow cytometry and tissue
factor assay. Microparticles were analyzed with a FACSCalibur®
(Becton Dickinson) flow cytometer by forward scatter and side
scatter. Microparticle concentration was determined as previously
described (30).
Beads were incubated with PE-conjugated anti–PSGL-1 antibody at 24C for 40 min, and then examined for fluorescence on
the FACSCalibur® flow cytometer. Background fluorescence was
determined by preincubation of the beads with a 50-fold excess
of the same antibody but lacking a fluorescent label before the addition of PE-conjugated anti–PSGL-1 antibody. Data were analyzed using CellQuest™ software.
Tissue factor activity was assayed with a one stage clotting time
(31). The values were converted to arbitrary units of procoagu-
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lant activity by comparison with a standard curve obtained using
a rabbit brain thromboplastin standard.
For analysis of PSGL-1 function on microparticles, P-selectin
IgG chimera–coated beads were prepared as the antibody-coated
beads, which were incubated with calcein-labeled microparticles
that had been pretreated with either 2 mM EDTA, 10 g/ml
anti–PSGL-1 monoclonal antibody (BD Biosciences), or 10 g/
ml of its isotype control.

Results
We have previously described the use of real-time in
vivo fluorescence and brightfield microscopy to capture
digital videos of thrombotic events in arterioles in the
mouse cremaster microcirculation (22). Using this system,
we have explored the role of P-selectin and PSGL-1 in a
pathway to fibrin formation in experimental thrombi generated in living mice.
Platelets Accumulate and Express P-Selectin at the Site of Endothelial Injury. P-selectin appears on the surface of activated platelets that have undergone degranulation of 
granules (7). Therefore, we studied P-selectin expression
on platelets incorporated into a developing thrombus in
vivo to determine whether platelet P-selectin is exposed to
flowing blood. Alexa 350–conjugated P-selectin antibody
was infused into the circulation of an anesthetized mouse.
Intravital widefield microscopy was performed to visualize
P-selectin fluorescence in one channel and the brightfield
image in a second channel after endothelial injury. Platelets
initially adhere and accumulate on the surface of the injured vessel wall (22). In the current experiments depicting
the earliest events of thrombus formation, no leukocyte
rolling was observed on the arterial wall or the arterial
thrombus. Platelet P-selectin expression was observed
within the thrombus during thrombus development in a
wild-type mouse (Fig. 1 A). However, in control experiments, no P-selectin antibody was detected in the thrombus of a P-selectin null mouse (Fig. 1 B), indicating that the
antibody is not trapped nonspecifically within the thrombus. The exposure of P-selectin in the developing thrombus of a wild-type mouse indicates platelet activation and
degranulation on the time scale of thrombus formation under the conditions used. Although only representative images are depicted, these experiments have been performed
in four mice of each genotype.
Tissue Factor Accumulates in the Developing Thrombus in
Wild-type Mice but Not PSGL-1 Null nor P-Selectin Null
Mice. We investigated tissue factor accumulation in wildtype mice and mice lacking PSGL-1 or P-selectin. Considering the critical nature of these experiments, we compared
our initial results using a commercially available sheep anti–
rabbit tissue factor antibody that cross reacts with mouse tissue factor (22) with rabbit antibodies against a synthetic
peptide based upon residues 152–166 of mouse tissue factor,
rabbit anti–mTF (152–166) antibodies, which we prepared
and characterized. Rabbit anti–mTF (152–166) antibodies
were immunoaffinity purified and characterized by Western
blot analysis. This antibody is reactive against a 43,000 mo-
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Figure 1. Expression of P-selectin in the developing
thrombus. P-selectin was localized in the developing
thrombus with Alexa 350–conjugated rat anti–mouse
P-selectin antibody. The Alexa 350 fluorochrome image,
collected digitally and presented as a red pseudocolor, is
merged with the brightfield image. The images depicted
are 160 s (wild-type mouse) and 200 s (P-selectin null
mouse) after laser-induced endothelial injury. The boundaries of the thrombus are indicated by the arrowheads. A,
wild-type mouse; B, P-selectin null mouse.

lecular weight band in mouse fibroblasts, corresponding to
tissue factor (Fig. 2 A, left). A minor higher molecular
weight band might be a tissue factor dimer. Furthermore,
this antibody is reactive with a recombinant mouse tissue
factor-Ig chimera (unpublished data). Rabbit anti–mTF
(152–166) antibodies do not inhibit tissue factor activity, as
measured in a linked chromagenic assay for tissue factor
stimulation of Factor X activation. Anti-mTF (152–166)
antibodies detected tissue factor in arterial thrombi in vivo.
Nonimmune IgG was minimally reactive with thrombi under identical conditions (Fig. 2 A, middle). These experiments were conducted with four mice. Images of tissue factor in thrombi during intravital microscopy using the rabbit
anti–mTF (152–166) antibodies were similar to those obtained with the sheep anti–rabbit tissue factor antibody (Fig.
2 A, right). We have used both anti-tissue factor antibodies
independently in these intravital experiments.
We previously demonstrated that blocking antibodies to
P-selectin infused into a baboon inhibited the formation of
a fibrin clot in a shunt thrombosis model although platelet
deposition was unaffected (11). Because fibrin generation is
initiated by tissue factor, we examined the role of P-selectin and PSGL-1 in tissue factor accumulation in the developing thrombus. Alexa 488–conjugated sheep anti–rabbit
tissue factor antibodies were infused into the circulation of
a wild-type mouse. After 5 min, vascular injury was induced in a cremaster muscle arteriole. Tissue factor accumulated into the thrombus after vessel injury (Fig. 2 B),
confirming our earlier results (22).
Endothelial injury led to thrombus formation in both the
PSGL-1 null mouse and the P-selectin null mouse. However, minimal tissue factor was incorporated into the
thrombus generated in either deficient mouse strain (Fig. 2
B). The initial time course of tissue factor accumulation in
the developing thrombus of a wild-type mouse, PSGL-1
null mouse, and P-selectin null mouse indicates that minimal tissue factor is associated with thrombi formed in
PSGL-1 null mice or P-selectin null mice, in contrast to
that of wild-type mice (Fig. 2 C).
Because tissue factor synthesis and appearance might be
altered by the level of P-selectin (32) or possibly PSGL-1
1588

expression, we studied wild-type mice to determine
whether blockade of P-selectin function just before thrombus formation would interfere with tissue factor accumulation in the thrombus. Thrombi (n  7) were formed in
wild-type mice and an additional seven thrombi were
formed after infusion of anti–P-selectin antibody. Data are
the mean
SEM. P-selectin antibody infused into wildtype mice before thrombus formation inhibited tissue factor accumulation in thrombi by 80% compared with tissue
factor accumulation in thrombi formed in the absence of
P-selectin antibody (Fig. 3 A). These results are qualitatively similar to that observed with the P-selectin null
mouse in the absence of anti–P-selectin antibodies.
Fibrin Accumulates in the Developing Thrombus in Wild-type
Mice but Is Decreased in PSGL-1 Null and P-Selectin Null
Mice. To determine whether the tissue factor observed in
the thrombus was biologically active, we studied the kinetics of fibrin accumulation in the developing thrombus using fibrin-specific antibodies (27). Alexa 660–conjugated
fibrin-specific antibody was infused into the anesthetized
mouse 5 min before the initiation of thrombus formation.
Fibrin was detected in the developing thrombus in the
wild-type mouse (Fig. 4 A, left), as previously demonstrated (22). Identical experiments performed using PSGL-1
null mice, P-selectin null mice, and wild-type mice treated
with hirudin to inhibit thrombin showed minimal fibrin
accumulation in the developing thrombus at 90 s (Fig. 4 A,
left). We have quantitated double label experiments of
platelet fluorescence and fibrin fluorescence from multiple
experiments (Fig. 4 A, right). The ratio of the integrated fibrin fluorescence to the integrated platelet fluorescence based upon results from individual thrombi derived from the average of two mice of each genotype and a
total of six thrombi is shown. To determine fluorescence
background in the absence of fibrin, hirudin, which blocks
fibrin formation, was used in wild-type mice and the integrated fibrin fluorescence to the integrated platelet fluorescence ratio was determined and subtracted from these
ratios in wild-type mice, PSGL-1 null mice, and P-selectin null
mice. The integrated fibrin fluorescence to the integrated
platelet fluorescence ratio in thrombi from the P-selectin
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Figure 2. Tissue factor accumulation in the developing arterial thrombus. (A) Left: characterization of rabbit anti–mTF
(152–166) antibodies. Western
blot of tissue factor with affinitypurified rabbit anti–mTF (152–
166) antibodies. STO cells, red
cells, and platelets were lysed and
the proteins in the lysate were
separated on a 10% SDS-PAGE
gel under reducing conditions.
Lanes 1 and 5, 5 g STO cell lysate; lanes 2 and 6, 7 g STO
cell lysate; lane 3, 5 g murine
red cell lysate; lane 4, 7 g murine red cell lysate. Lanes 1–4
were developed with anti–
mouse tissue factor antibody and
lanes 5 and 6 were developed
with an irrelevant antibody,
anti-CD41. Arrow indicates
molecular weight of tissue factor. Middle: comparison of tissue
factor fluorescence detected with
rabbit anti–mTF (152–166) antibodies (bar 2) or nonimmune
IgG control (bar 1). The ratio of
the integrated tissue factor fluorescence (FTF) to the integrated
platelet fluorescence (FP) in
thrombi generated in wild-type
mice is shown based upon multiple independent experiments.
P 0.0042. Right: image of tissue factor in a thrombus detected
using rabbit anti–mTF (152–166)
antibodies. Top: Thrombus detected with anti-mTF (152–166)
antibodies and anti-CD41 antibody directed against platelets.
Bottom: Thrombus imaged with
nonimmune IgG and anti-CD41
antibody directed against platelets. Red, platelets; green, tissue
factor; yellow, platelets plus tissue factor. (B) Intravital images
of arterial thrombi. Tissue factor
was detected using Alexa 488–
conjugated anti-tissue factor antibodies infused into the systemic
circulation. The fluorescence
image, recorded digitally, is presented as the green pseudocolor.
Brightfield images of the thrombi are indicated by arrowheads. Images are representative of 12 thrombi formed in 2 arterioles in 2 mice of each genotype.
(C) Time course of tissue factor antigen accumulation in the developing arterial thrombus in wild-type and genetically altered mice. Tissue factor was detected using sheep anti–tissue factor antibodies infused into the systemic circulation followed by Alexa 660–conjugated donkey anti–sheep IgG. Sheep
IgG was substituted for anti-tissue factor antibody, control. Each curve represents the raw digital data of a single representative experiment. WT, wildtype mouse; PSGL , PSGL-1 null mouse; P-selectin , P-selectin null mouse.

null mice and in thrombi from the PSGL-1 null mice was
approximately 0, in contrast to this ratio determined in
wild-type mice. Statistical analysis using the t test shows
that this integrated fibrin fluorescence to the integrated
platelet fluorescence ratio decrease is significant (P 0.05).
Error bars indicate standard error of the mean. Although
the size and rate of enlargement of the platelet thrombi
vary in these different experiments, only the wild-type
1589
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mouse shows the development of significant amounts of fibrin colocalized with platelets (Fig. 4 B, yellow).
We have previously demonstrated that anti–P-selectin
antibodies inhibited fibrin deposition during experimental
thrombosis in a baboon model (11). To revisit this experiment in a mouse model, P-selectin antibody was infused
into a wild-type mouse before thrombus formation and fibrin was detected with a fibrin-specific antibody. Thrombi

Figure 3. Anti–P-selectin antibodies inhibit tissue factor and fibrin
accumulation in the developing thrombus in wild-type mice. (A) Tissue
factor in the thrombus formed was quantitated using Alexa 488–conjugated sheep anti–tissue factor antibodies from images derived by high
speed widefield microscopy. Thrombi were formed in the absence of
anti–P-selectin antibody in a wild-type mouse (bar 1). Subsequently,
anti–P-selectin antibody (0.5 g/g body weight) was infused and thrombi
were formed in the presence of antibody (bar 2) between 5 and 30 min
after antibody infusion. Data are at 60 s after injury and from seven
thrombi formed in four arterioles before infusion of antibody and seven
thrombi formed in four arterioles after infusion of antibody. Two mice
were used. Mean SEM. (B) Experimental protocol was the same as described above except that fibrin was detected using Alexa 660–conjugated
anti-fibrin–specific antibodies.

The Journal of Experimental Medicine

(n  7) were formed in wild-type mice and an additional
seven thrombi were formed after infusion of anti–P-selectin antibody. Data are the mean SEM. Thrombi formed
in the presence of P-selectin antibody contained 60% less

fibrin than thrombi formed in the absence of P-selectin antibody (Fig. 3 B). These results are quantitatively similar to
those observed with the P-selectin null mouse in the absence of anti–P-selectin antibodies.

Figure 4. Fibrin deposition in the developing
thrombus. (A) Left: Alexa 660–conjugated anti–mouse
fibrin antibody and rat anti–mouse CD41 detected
with Alexa 488–conjugated chicken anti–rat IgG were
used to detect fibrin (red) and platelets (green). Overlap
of the platelet and fibrin images is shown as a composite (yellow). When used, hirudin (1 U/g body weight)
was infused immediately before initial thrombus formation. Fibrin and platelets were observed in thrombi
formed 60 s after vessel injury. Images are representative of 10 thrombi formed in 6 arterioles in 3 mice of
each genotype. Right: the ratio of the integrated fibrin
fluorescence (FF) to the integrated platelet fluorescence
(FP) in thrombi generated in wild-type mice, PSGL-1
null mice, and P-selectin null mice is shown (black)
based upon multiple independent experiments. The
fluorescence background in the absence of fibrin was
determined in wild-type mice treated with hirudin.
Error bars indicate standard error of the mean whereas
* indicates statistical significance. (B) Images of the developing thrombus from 0–90 s. Platelets (green), fibrin
(red), and platelet/fibrin composite (yellow). (C) Time
course of fibrin formation in the developing thrombi of
wild-type and genetically altered mice. Each curve represents the raw digital data of a single representative experiment. WT, wild-type mouse; PSGL , PSGL-1
null mouse; P-selectin , P-selectin null mouse.
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The time course of fibrin accumulation in the developing thrombus of a wild-type mouse, PSGL-1 null mouse,
and P-selectin null mouse indicates that fibrin appearance
correlates to the presence of tissue factor (Fig. 4 C). In the
absence of tissue factor accumulation in the developing
thrombus, as in the PSGL-1 null and P-selectin null mice
(Fig. 2 C), there is minimal fibrin accumulation.
To compare the time course and localization of platelet
deposition, tissue factor accumulation, and fibrin formation
in the thrombus of a wild-type mouse or a mouse deficient
in PSGL-1 or P-selectin, we monitored platelets, tissue factor, and fibrin simultaneously within the context of the
brightfield image of the microcirculation. Intravital four
channel video images were obtained that visualized platelets (red), tissue factor (green), and fibrin (blue) in the microcirculation (black/white). Colocalization of tissue factor
and platelets (yellow), tissue factor and fibrin (turquoise),
fibrin and platelets (magenta), and fibrin, tissue factor, and
platelets (white) are also depicted. Images were collected
continuously before, during, and after laser injury. The
fluorescence intensities of tissue factor, fibrin, and platelets
are not calibrated, and thus do not reflect the relative concentration of components to each other. Furthermore, the
signal to noise level is too low to be certain of the timing of
tissue factor detection relative to platelet and fibrin appearance. At time 0 s, the baseline fluorescence in each fluorescence channel was adjusted in the initial image at the time
of injury to zero fluorescence. In this example of thrombus
formation in a wild-type mouse (Fig. 5, left) at time 20 s,
platelets and tissue factor are accumulating on the vessel
wall. As the platelet thrombus expands at time 75 s and
time 85 s, fibrin appears within the thrombus. At time
100 s, platelet thrombus expansion continues as the
quantity of fibrin and tissue factor on the proximal edge increases while fibrin and tissue factor extend distally within
the platelet thrombus. Fibrin extends through much of the
platelet thrombus, although the distal end of the thrombus
remains exclusively composed of platelets.
Similar experiments were performed using either PSGL-1
null or P-selectin null mice. In the PSGL-1 null mouse,
platelets accumulated at the site of injury but minimal tissue
factor or fibrin is observed in the growing thrombus (Fig.
5, middle). Similar observations were made in the growing
arterial thrombus of the P-selectin null mouse (Fig. 5,
right). These results emphasize that the tissue factor that accumulates at the leading edge of the thrombus and along
the vascular wall is dependent upon the presence of both
PSGL-1 and P-selectin. The fibrin that forms correlates to
the amount of tissue factor observed. These in vivo experiments demonstrate that platelets accumulate rapidly in the
developing thrombi in wild-type mice, PSGL-1 null mice,
and P-selectin null mice. However, only in wild-type mice
is this event followed by significant fibrin deposition.
Mouse Microparticles Accumulate in the Developing Thrombus. To determine the mechanism by which P-selectin
and PSGL-1 influence tissue factor accumulation in the developing thrombus, we examined the source of tissue factor. Rauch et al. (21) have previously shown that anti1591
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Figure 5. Intravital imaging of platelet, tissue factor, and fibrin deposition in the developing thrombus of a wild-type mouse, PSGL-1 null
mouse, or P-selectin null mouse after endothelial injury. Alexa 660–conjugated CD41 Fab fragments, Alexa 488–conjugated sheep anti–tissue
factor antibodies, and Alexa 350–conjugated mouse anti–fibrin antibodies
were infused into the systemic circulation. Representative composite images of the developing thrombus are shown. Red, platelets; green, tissue
factor; blue, fibrin; yellow, platelets plus tissue factor; turquoise, tissue
factor plus fibrin; magenta, platelets plus fibrin; white, platelets plus fibrin
plus tissue factor. Fluorescence intensity in each channel was zeroed in
images obtained before thrombus formation. Videos were continuously
collected in four channels before and during laser injury and during
thrombus development. To simplify analysis of the composite image, the
dynamic range of the intensity of each pseudocolor was minimized. Images are representative of four thrombi formed in each of the mouse
strains. Left, wild-type mouse; middle, PSGL-1 null mouse; right,
P-selectin null mouse.

CD15 antibodies inhibit blood-borne tissue factor association with platelets in vitro, so we considered sources of tissue factor associated with CD15. CD15, a carbohydrate antigen, is broadly distributed on cell surface glycoproteins
and glycolipids on myeloid cells and is a component of the
counterreceptor of L-selectin, E-selectin, and P-selectin
(33, 34). Because tissue factor is known to be inducible on
the surface of monocytes and may also be expressed on
granulocytes, we examined developing arterial thrombi for
leukocytes and leukocyte-derived microparticles as a potential source of tissue factor. In our in vivo model of arterial thrombosis, no leukocytes either interacted with or
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were incorporated into the thrombus during the initial
phase of thrombus development when tissue factor first appears in the thrombus (35). Therefore, we hypothesized
that subcellular components circulating in blood that are
derived from leukocytes, including microparticles, might
include tissue factor physically associated with PSGL-1.
Such tissue factor- and PSGL-1–bearing species would
bind to P-selectin expressed on activated platelets in the arterial thrombus via PSGL-1, concentrating tissue factor in
the thrombus.
Blood cells were isolated from anticoagulated mouse
blood and incubated with calcein AM to introduce a fluorescent probe into the cytoplasm (Fig. 6 A, top left). After activation of these cells with the calcium ionophore A23187, a
large number of fluorescent microparticles were generated

(Fig. 6 A, bottom left). These microparticles were isolated by
centrifugation (Fig. 6 A, bottom middle) and their size was
compared with calibrated microspheres of 0.93-m diameter (Fig. 6 A, top middle). 95% of the microparticles were
smaller than 1 m, as estimated by scattering measurements
by flow cytometry. A histogram of the microparticles indicates their intense fluorescence (Fig. 6 A, right).
These microparticles were infused into a wild-type
mouse while the cremaster muscle vascular window was
under direct observation. Although fluorescent microparticles could be seen rapidly flowing in the microcirculation,
there was no interaction of these particles with the vessel
wall of the arteriole (Fig. 6 B, 0s). Upon endothelial injury
and thrombus formation, fluorescent microparticles became
rapidly associated with the developing thrombus (Fig. 6 B).

Figure 6. Calcein-labeled mouse microparticles accumulate into arterial thrombi. A leukocyte-rich blood cell
preparation was labeled with calcein AM. (A) Flow cytometry. Two distinct populations are shown on the top left: a
small, highly labeled cell population (platelets) and a larger
population with lower calcein labeling (leukocytes). Upon
the addition of A23187, a third population of calceinlabeled particles appeared (bottom left). 0.93 m calibration microbeads were used to determine the limits of size
of particles 1 m (top middle). After the addition of
A23187, the cells were removed by centrifugation, with
95% of the remaining particles in the supernatant 1
m (bottom middle). These microparticles exhibited calcein fluorescence (black) compared with particles generated under the same conditions without the addition of
calcein (gray; right). (B) Calcein-labeled microparticles
were injected into the mouse circulation and their incorporation into arterial thrombi monitored over time by
real-time widefield fluorescence videomicroscopy. Images
are shown at 0, 20, and 40 s after thrombus formation.
Left, brightfield image; arrow heads, the lumenal edge of
the thrombus; middle, fluorescence image; right, composite brightfield and fluorescence images. Experiments are
representative of three independent experiments. (C) Calcein-labeled microparticles derived from WEHI cells, a
murine monocyte-like cell line, were infused into wildtype mice (top) or P-selectin null mice (bottom). The
images were obtained 60 s after endothelial injury and the
initiation of thrombus formation. Left, brightfield image;
arrow heads, the lumenal edge of the thrombus; middle,
fluorescence image; right, composite brightfield and fluorescence images.
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Because microparticles derived from mononuclear cells
are contaminated with microparticles derived from platelets
that contaminate the cell preparation, we prepared microparticles from a mouse monocyte-like cell line, WEHI.
WEHI cells express functional PSGL-1 and were the
source of mouse PSGL-1 cDNA (36). WEHI cells in culture were loaded with calcein AM. After activation of these
cells with the calcium ionophore A23187, a large number
of fluorescent microparticles were generated and isolated
by centrifugation. Light scattering measurements via flow
cytometry revealed that these microparticles were 1 m
in diameter. The WEHI microparticle preparation was infused into either a wild-type mouse or a P-selectin null
mouse while the cremaster muscle vascular window was
under direct observation. Although fluorescent microparticles could be seen rapidly flowing in the microcirculation,
there was no interaction of these particles with the vessel
wall of the arteriole. Upon endothelial injury in the arteriole and thrombus formation, fluorescent microparticles became associated with the leading edge of the thrombus
generated in wild-type mice (Fig. 6 C). However, microparticles did not accumulate in the P-selectin null mice although occasional transient interaction of microparticles
with the lumenal edge of the thrombus was observed (Fig.
6 C). These results indicate that PSGL-1–bearing microparticles in the circulating blood localize in thrombi that
express P-selectin through P-selectin–PSGL-1 interaction
but do not accumulate in thrombi lacking P-selectin.
Tissue Factor and PSGL-1 on Blood Microparticles. We
examined microparticles in mouse and human plasma for
the coexpression of both tissue factor antigen and PSGL-1
antigen. Anticipating low levels of such species in normal
plasma, we developed sensitive methodology for detecting
tissue factor and PSGL-1 by examining microparticles derived from human mononuclear cells. Supernatant from
these cells were examined for tissue factor activity and for
the presence of particles. As shown in Fig. 7 A, left, the supernatant of the mononuclear cells contained 1,410 particles/l and low but measurable tissue factor activity. This
activity was inhibited by anti-tissue factor antibodies. If the
mononuclear cells were stimulated with LPS, the cell supernatant included 1,869 particles/l with significantly
higher tissue factor activity. This is consistent with the
known induction of tissue factor biosynthesis by LPS (37).
The concomitant stimulation of mononuclear cells with
both LPS and the calcium ionophore A23187 led to 5,000
particles/l and a 20-fold stimulation of tissue factor activity. Tissue factor activity could be removed from the cell
supernatant by ultracentrifugation, indicating that the tissue
factor measured is not a protein free in solution (Fig. 7 A,
right). These results are consistent with tissue factor–bearing microparticles in the cell supernatant of stimulated and
unstimulated mononuclear cells.
Calcein-labeled microparticles were evaluated for the
presence of functional PSGL-1. Using P-selectin IgG
beads, we captured fluorescent microparticles in the presence of calcium (Fig. 7 B). In the presence of EDTA (Fig.
7, left) or a blocking antibody to PSGL-1 (Fig. 7 B,
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right), the interaction of microparticles with P-selectin
IgG was inhibited.
Having shown the presence of functional tissue factor
and functional PSGL-1 on microparticles, we examined
mononuclear cell supernatant and platelet-poor plasma for
the presence of PSGL-1 antigen after concentration of tissue factor–positive microparticles on beads containing antitissue factor. Anti-tissue factor beads were incubated with
mononuclear cell supernatant or platelet-poor plasma, and
the beads were examined by flow cytometry for PSGL-1
antigen. Tissue factor–positive microparticles from mononuclear cell supernatant or platelet-poor plasma both exhibited PSGL-1 antigen (Fig. 7 C). Control beads containing
an isotype- matched control antibody in place of anti-tissue
factor antibody did not bind to microparticles expressing
PSGL-1. These results demonstrate the presence of microparticles in platelet-poor plasma or mononuclear cell supernatant that contain both tissue factor and PSGL-1.
Tissue factor–positive microparticles from platelet-poor
plasma were examined to identify their cellular source (Fig.
7 D). These microparticles were positive for PSGL-1
(CD162), CD11b, and CD14, consistent with the phenotype of monocytes. They were negative for CD66b, a
granulocyte marker.

Discussion
P-selectin and PSGL-1 are cell adhesion molecules that
play a critical role in the initial capture and tethering
events associated with leukocyte interaction with the endothelium of the vasculature. P-selectin, present in the
storage granules of platelets and endothelial cells, is translocated upon cell activation to the plasma membrane
where it is expressed on the membrane surface. PSGL-1, a
mucinous glycoprotein, is constitutively expressed on the
leukocyte plasma membrane. During the initial phases of
inflammation, leukocyte rolling is mediated on the vasculature by these adhesion molecules. PSGL-1 appears to be
the dominant P-selectin ligand during leukocyte rolling,
although this glycoprotein also serves as an E-selectin
ligand for leukocyte rolling and lymphocyte migration in
vivo (24, 25, 38). In this study, we have broadened the
known functions of PSGL-1 to propose a role in tissue
factor accumulation and fibrin formation during the development of experimental thrombi through the concentration of PSGL-1–bearing microparticles in the developing thrombus. This provides a molecular basis for our
previous observation of the ability of anti–P-selectin antibodies to inhibit fibrin formation during thrombogenesis
(11).
The longstanding model of blood coagulation has been
that (a) blood clotting is initiated via tissue factor, (b) tissue
factor is not exposed to blood but is constitutively expressed on nonvascular cells, and (c) upon vascular injury,
tissue factor on nonvascular cells comes in contact with
flowing blood, initiating a series of linked, enzymatic reactions that culminate in the generation of fibrin and a fibrin
clot. A number of recent observations are not consistent
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Figure 7. Functional tissue factor
and PSGL-1 on microparticles and
presence of microparticles positive
for tissue factor and PSGL-1. (A)
Monocytes produce tissue factor–
bearing microparticles. The medium from monocytes isolated and
cultured in the absence of any additions, in the presence of LPS, or in
the presence of LPS and A23187 was
centrifuged for 30 s at 14,000 g to
remove cells. The microparticles in
the supernatant were counted and
assayed for the presence of tissue factor activity. Left: open bars, tissue
factor activity in the supernatant;
gray bars, tissue factor activity after
addition of anti-tissue factor antibody; black bars, tissue factor activity after the addition of nonimmune
IgG. Right: supernatant was analyzed for the presence of microparticles before and after ultracentrifugation at 150,000 g for 120 min. Open
bar, before ultracentrifugation; black
bar, after centrifugation. The number of particles per microliter is indicated. (B) Microparticles express
functional PSGL-1. P-selectin Ig
chimera adsorbed to beads was incubated with calcein-labeled microparticles in the presence of buffer
(black) or EDTA (gray; left) and
anti–PSGL-1 antibody (gray) or isotype-matched control antibody
(black; right). (C) Flow cytometric
analysis of tissue factor–positive microparticles concentrated from human platelet–poor plasma (PPP; bottom)
and
mononuclear
cell
supernatant (MNC; top). These microparticles were incubated with
beads containing tissue factor antibody (right) and beads containing
nonimmune IgG (left). Black, fluorescently labeled anti–PSGL-1 antibody; gray, fluorescently labeled
anti–PSGL-1 antibody plus 50-fold
excess of unlabeled anti–PSGL-1
antibody. (D) Flow cytometric
analysis of tissue factor–positive microparticles concentrated from human platelet null plasma. CD162
(PSGL-1), CD11b, CD14, CD66b.
Top, beads coated with anti-tissue
factor antibody; bottom, beads
coated with nonimmune IgG; black,
fluorescently labeled specific antibody; gray, fluorescently labeled
specific antibody plus 50 fold excess
of unlabeled specific antibody.

with this model. First, tissue factor circulates in blood at
levels of 100–150 pg per ml (17–19). Second, tissue factor is associated with thrombi formed on pig arterial media
or collagen-coated glass slides exposed to flowing human
blood in vitro (20). The association of tissue factor–positive
granules with platelets in this thrombus was inhibited by
anti-CD15 (21), suggesting a role for this carbohydrate an1594

tigen in this interaction. Third, this model does not include
a role for P-selectin. Yet, antibodies to P-selectin inhibit fibrin formation (11), P-selectin null mice have a prolonged
bleeding time (39), and thrombi formed in vitro indicate
architectural differences when formed from blood of wildtype and P-selectin null mice (40). Using digital videomicroscopy to image the microcirculation of a living mouse,
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we have analyzed the role of PSGL-1 and P-selectin in
thrombosis in vivo.
In this and an earlier study, we have observed platelet
deposition, P-selectin expression, tissue factor localization,
and fibrin formation during thrombus formation in wildtype mice after vascular injury of the arterial vessel wall (22).
We now show that tissue factor accumulation in the thrombus is minimal in mice lacking either PSGL-1 or P-selectin.
During the earliest stages of thrombus development in wildtype mice, tissue factor accumulates at the leading edge of
the developing thrombus, where plasma tissue factor first
comes in contact with platelet P-selectin in the thrombus,
and at the thrombus-vessel wall interface, where tissue factor might be derived from the vessel wall or from plasma
captured by endothelial cell P-selectin. We show that tissue
factor in both sites is minimal in P-selectin null mice and
PSGL-1 null mice. Andre et al. (32) demonstrated that elevated soluble P-selectin levels maintained in a mouse for
22 h or P-selectin constitutively expressed on the mouse
endothelium leads to increased circulating microparticles,
some expressing tissue factor. We considered that the minimal tissue factor in the thrombi of mice lacking either
PSGL-1 or P-selectin in our experiments might be due to
decreased numbers of tissue factor–bearing microparticles.
However, we show that an inhibitory P-selectin antibody
infused into a wild-type mouse just before endothelial injury blocks tissue factor and fibrin accumulation in the
thrombus. These results parallel the results of P-selectin antibody inhibition of fibrin clot formation in a baboon model
(11). Thus, chronic deficiency of P-selectin, as in the P-selectin null mouse, is not responsible for the absence of tissue
factor in the thrombus. Because both the P-selectin null
mouse and PSGL-1 null mouse demonstrate decreased tissue factor accumulation in the developing thrombus, direct
interaction between P-selectin and tissue factor is not responsible for tissue factor accumulation and is not the basis
for tissue factor–mediated transfer of microparticles to platelets (21). Furthermore, the report of tissue factor in platelets
(41) and inference that platelet tissue factor contributes to
thrombus formation does not explain the role of PSGL-1 in
tissue factor accumulation in thrombi in our in vivo experiments. The tissue factor accumulated in the developing
thrombus is biologically active because the quantity of tissue
factor antigen correlates with the fibrin level that forms in
the thrombus. Based upon these in vivo studies, we support
the concept of Giesen et al. (20) that one pathway for the
propagation of blood coagulation after endothelial injury involves the accumulation and localization of blood-borne tissue factor on microparticles onto the platelet thrombus.
Although the absence of PSGL-1 or P-selectin greatly
reduces the observed tissue factor in the developing thrombus, some tissue factor can be detected. This raises the
question whether there exists an alternate mechanism that
can deliver microparticles to the platelet thrombus or
whether our observation is due to platelet tissue factor (41).
Given the minimal amount of tissue factor and fibrin observed in the P-selectin null mice and the PSGL-1 null
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mice, it would not appear that this possible alternate pathway is critical for fibrin formation.
Based upon the known presence of low concentrations
of tissue factor in normal blood, the presence of tissue factor in thrombi formed in vitro and inhibition of tissue factor–bearing microparticles interaction with platelets by
anti-CD15 antibodies (21), we hypothesized that PSGL-1
might play a role in the concentration of tissue factor–positive leukocyte-derived microparticles into the developing
thrombus. CD15, a carbohydrate antigen, is broadly expressed on glycoproteins and glycolipids on myeloid cells.
CD15 antibody inhibited the binding of platelets to tissue
factor–positive microparticles generated from THP-1 cells,
suggesting a role for CD15 in this interaction (21). The
P-selectin ligand expressed on myeloid cells, along with
most other plasma membrane glycoproteins on these cells,
includes CD15 as a component (33). This P-selectin ligand
has been identified as a glycoprotein, PSGL-1 (9, 10).
PSGL-1, an integral membrane protein including sialylated
and fucosylated core 2 glycans, is found on the plasma
membrane of neutrophils, monocytes, and certain lymphocyte subsets. Because monocytes express PSGL-1 and can
be induced to express tissue factor, the PSGL-1–dependent
delivery of tissue factor to the platelet thrombus expressing
P-selectin could be mediated by blood leukocytes. However, in our in vivo imaging experiments, we observe no
leukocyte incorporation into the developing thrombus
during the initial minutes after arterial injury (35). Because
tissue factor–positive microparticles have been shown in in
vitro experiments to be associated with platelets in the
thrombus (21), these particles might express PSGL-1 necessary for fibrin formation.
Blood under normal and pathophysiologic conditions
contains procoagulant microparticles (42). Several lines of
evidence suggest that microparticles derived from platelets
(43–45), leukocytes (46–48), endothelial cells (49, 50), and
smooth muscle cells (51) could play a role in blood coagulation. Furthermore, it is well established that microparticles express phosphatidylserine on the membrane surface
that can provide the catalytic surface for the tenase and prothrombinase complexes, along with antigens characteristic
of their cellular origin (52).
We have generated mouse microparticles that are intensely fluorescently labeled and infused them into a living
mouse while monitoring the microcirculation of the cremaster muscle. In the absence of endothelial injury, there
was no evidence of microparticle–vessel wall interaction in
the arterial microcirculation. This parallels the observation
that leukocyte rolling is not present on the arterial limb.
However, upon endothelial injury and thrombus formation, we observe rapid accumulation of fluorescent microparticles into the developing thrombus. Although only a
very small fraction of the blood microparticles were fluorescently labeled, real-time video imaging demonstrated
their instant capture solely on the growing thrombus in a
mechanism dependent upon P-selectin. No interaction was
observed between microparticles and the endothelium. Mi-
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croparticles were only transiently associated with developing thrombi in the P-selectin null mouse.
To explore this in a system where ample starting material
was available, we first looked for tissue factor–positive,
PSGL-1 microparticles in human platelet–poor plasma.
These microparticles are 1 m in diameter. Low concentrations of both tissue factor and PSGL-1 precluded direct
measurement of these antigens on the particle surface by
flow cytometry. Therefore, we concentrated tissue factor–
positive microparticles on polystyrene beads coated with
anti-tissue factor antibody. These beads were subsequently
shown to be positive for PSGL-1 antigen by flow cytometry. This link between tissue factor and PSGL-1, coupled
with our data showing that there is functional PSGL-1 and
active tissue factor on microparticles and that such particles
are incorporated into arterial thrombi, implicate PSGL-1 in
a new role as a cell adhesion molecule on microparticles involved with delivering tissue factor to the developing
thrombus.
The tissue factor and Factor VIIa concentrations in normal blood are low. Although encryption of tissue factor
may also contribute to the absence of spontaneous coagulation in flowing blood (53), we hypothesize that upon
reaching a threshold level during concentration in the
platelet thrombus, tissue factor can complex with Factor
VIIa and initiate blood coagulation, culminating in the
generation of fibrin. It remains to be seen whether tissue
factor within the thrombus is part of a physiologically critical pathway of fibrin generation or whether it is a supplement to mechanisms involving tissue factor within the
damaged vessel wall.
P-selectin and PSGL-1 are important cell adhesion molecules that mediate the initial steps in the inflammatory
pathway and lymphocyte migration (24, 25, 54). Our results demonstrate that these adhesion molecules also play a
role in thrombus formation in capturing tissue factor–bearing plasma microparticles into the site of vascular injury
where platelet P-selectin can bind to PSGL-1 on these microparticles. Although much attention has been focused on
the anti-inflammatory applications of the blockade of the
selectins and their ligands, inhibition of P-selectin or
PSGL-1 function might be a useful pharmacologic target
for antithrombotic therapy.
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